High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases

Show simple item record

dc.contributor.author Peltonen, Reetta
dc.contributor.author Hagström, Jaana
dc.contributor.author Tervahartiala, Taina
dc.contributor.author Sorsa, Timo
dc.contributor.author Haglund, Caj
dc.contributor.author Isoniemi, Helena
dc.date.accessioned 2021-10-06T22:44:16Z
dc.date.available 2022-02-11T18:45:17Z
dc.date.issued 2021-02
dc.identifier.citation Peltonen , R , Hagström , J , Tervahartiala , T , Sorsa , T , Haglund , C & Isoniemi , H 2021 , ' High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases ' , Oncology , vol. 99 , no. 3 , pp. 144-160 . https://doi.org/10.1159/000510609
dc.identifier.other PURE: 149843216
dc.identifier.other PURE UUID: 24c345fa-f082-4b21-b550-42f1d09a75c4
dc.identifier.other WOS: 000625238300002
dc.identifier.other ORCID: /0000-0001-6079-7881/work/92591627
dc.identifier.uri http://hdl.handle.net/10138/335019
dc.description.abstract Introduction: The liver metastases of colorectal cancer (CRC) can be surgically treated in selected cases, with continuously improving results. Matrix metalloproteinases (MMPs) contribute to cancer invasion by degrading the extracellular matrix, and elevated levels of MMP-2, MMP-8, and MMP-9 have been detected in several malignancies. Myeloperoxidase (MPO) is a mediator of tissue damage that can oxidatively activate latent MMPs. We evaluated the prognostic value of MMP-2, MMP-8, and MMP-9 in tissue samples of primary tumors and liver metastases and the pre- and postoperative serum levels of MMP-8, MMP-9, and MPO in CRC patients undergoing liver resection. Methods: Tissue and serum samples were obtained from 111 patients who had primary colorectal tumors and their liver metastases surgically treated at the Helsinki University Hospital between 1988 and 2007. Tissue expression of MMP-2, MMP-8, and MMP-9 in primary tumors and liver metastases was evaluated by immunohistochemistry. Pre- and postoperative serum concentrations of MMP-8, MMP-9, and MPO were determined using a time-resolved immunofluorometric assay or commercially available enzyme-linked immunosorbent assay kits. Clinical data were retrieved from patient records and the Central Statistical Office of Finland. Associations with disease-free survival (DFS) and overall survival (OS) were estimated using Cox regression analysis and the Kaplan-Meier method. Results: High expression of MMP-9 in colorectal tumor tissue was associated with better DFS (p = 0.010), and high preoperative MPO in serum with improved DFS and OS (p < 0.001 and p = 0.014, respectively). The prognostic significance varied according to gender, age, and the synchronicity of liver metastases. Conclusion: Low preoperative MPO in serum might identify patients at high risk of recurrence and death after resection of colorectal liver metastases. Elevated preoperative MPO and high expression of MMP-9 in colorectal tumor tissue indicate an improved prognosis. The use of these biomarkers should be adjusted according to clinical characteristics. en
dc.format.extent 17
dc.language.iso eng
dc.relation.ispartof Oncology
dc.rights unspecified
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject 3122 Cancers
dc.subject Colorectal cancer
dc.subject Liver resection
dc.subject Matrix Metalloproteinase 9
dc.subject Myeloperoxidase
dc.subject Prognosis
dc.subject Colorectal cancer
dc.subject Liver resection
dc.subject Matrix metalloproteinase 9
dc.subject Myeloperoxidase
dc.subject Prognosis
dc.title High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases en
dc.type Article
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization University of Helsinki
dc.contributor.organization Helsinki University Hospital Area
dc.contributor.organization IV kirurgian klinikka
dc.contributor.organization HUS Head and Neck Center
dc.contributor.organization Medicum
dc.contributor.organization CAN-PRO - Translational Cancer Medicine Program
dc.contributor.organization Department of Pathology
dc.contributor.organization Oral Pathology
dc.contributor.organization Doctoral Programme in Oral Sciences
dc.contributor.organization University Management
dc.contributor.organization Clinicum
dc.contributor.organization Suu- ja leukakirurgian yksikkö
dc.contributor.organization II kirurgian klinikka
dc.contributor.organization Department of Surgery
dc.contributor.organization Research Programs Unit
dc.contributor.organization HUSLAB
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1159/000510609
dc.relation.issn 0030-2414
dc.rights.accesslevel openAccess
dc.type.version acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
PeltonenRS_Oncology2020_final_version_Tuhat.pdf 1.491Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record